Venatorx Pharmaceuticals, Incorporated, Malvern, Pennsylvania, USA.
UNT System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0055221. doi: 10.1128/AAC.00552-21.
There is an urgent need for oral agents to combat resistant Gram-negative pathogens. Here, we describe the characterization of VNRX-5236, a broad-spectrum boronic acid β-lactamase inhibitor (BLI), and its orally bioavailable etzadroxil prodrug, VNRX-7145. VNRX-7145 is being developed in combination with ceftibuten, an oral cephalosporin, to combat strains of expressing extended-spectrum β-lactamases (ESBLs) and serine carbapenemases. VNRX-5236 is a reversible covalent inhibitor of serine β-lactamases, with inactivation efficiencies on the order of 10 M · sec, and prolonged active site residence times (, 5 to 46 min). The spectrum of inhibition includes Ambler class A ESBLs, class C cephalosporinases, and class A and D carbapenemases (KPC and OXA-48, respectively). Rescue of ceftibuten by VNRX-5236 (fixed at 4 μg/ml) in isogenic strains of Escherichia coli expressing class A, C, or D β-lactamases demonstrated an expanded spectrum of activity relative to oral comparators, including investigational penems, sulopenem, and tebipenem. VNRX-5236 rescued ceftibuten activity in clinical isolates of expressing ESBLs (MIC, 0.25 μg/ml), KPCs (MIC, 1 μg/ml), class C cephalosporinases (MIC, 1 μg/ml), and OXA-48-type carbapenemases (MIC, 1 μg/ml). Frequency of resistance studies demonstrated a low propensity for recovery of resistant variants at 4× the MIC of the ceftibuten/VNRX-5236 combination. , whereas ceftibuten alone was ineffective (50% effective dose [ED], >128 mg/kg), ceftibuten/VNRX-7145 administered orally protected mice from lethal septicemia caused by Klebsiella pneumoniae producing KPC carbapenemase (ED, 12.9 mg/kg). The data demonstrate potent, broad-spectrum rescue of ceftibuten activity by VNRX-5236 in clinical isolates of cephalosporin-resistant and carbapenem-resistant .
目前急需口服药物来对抗耐药性革兰氏阴性病原体。在这里,我们描述了广谱硼酸β-内酰胺酶抑制剂(BLI)VNRX-5236及其口服生物利用度前药 VNRX-7145 的特性。VNRX-7145 与口服头孢菌素头孢替坦联合开发,用于对抗表达超广谱β-内酰胺酶(ESBLs)和丝氨酸碳青霉烯酶的菌株。VNRX-5236 是一种可逆的丝氨酸β-内酰胺酶共价抑制剂,其失活效率约为 10 M·sec,并且活性部位停留时间延长(5 至 46 分钟)。抑制谱包括 Ambler 类 A ESBLs、C 类头孢菌素酶以及 A 类和 D 类碳青霉烯酶(分别为 KPC 和 OXA-48)。在表达 A、C 或 D 类β-内酰胺酶的大肠杆菌同基因菌株中,VNRX-5236(固定在 4μg/ml)对头孢替坦的挽救实验表明,与口服对照物(包括研究用青霉素类药物、 sulopenem 和 tebipenem)相比,其具有更广泛的活性谱。VNRX-5236 挽救了表达 ESBLs(MIC,0.25μg/ml)、KPC(MIC,1μg/ml)、C 类头孢菌素酶(MIC,1μg/ml)和 OXA-48 型碳青霉烯酶(MIC,1μg/ml)的临床分离株中头孢替坦的活性。耐药性研究的频率表明,在头孢替坦/VNRX-5236 组合的 4 倍 MIC 下,恢复耐药变体的可能性较低。相比之下,单独使用头孢替坦无效(50%有效剂量[ED],>128mg/kg),而口服给予头孢替坦/VNRX-7145 可保护小鼠免受产 KPC 碳青霉烯酶的肺炎克雷伯菌引起的致命败血症(ED,12.9mg/kg)。这些数据表明,VNRX-5236 可有效广泛地恢复头孢替坦在头孢菌素耐药和碳青霉烯耐药的临床分离株中的活性。